|
|
Research progress in etiology and pathogenesis and treatment of connective tissue disease-associated interstitial lung disease in traditional Chinese medicine |
LIANG Yanxia1 FAN Maorong1 WANG Bing1 ZHAO Yuan1 MA Hui2 ZHANG Ziran3 CONG Xiaodong1 |
1.Department of Pulmonary Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China;
2.Department of Traditional Chinese Medicine, Beijing Sijiqing Hospital, Beijing 100089, China;
3.Department of Traditional Chinese Medicine, Urumqi Maternal and Child Health Hospital, Xinjiang Uygur Autonomous Region, Urumqi 830001, China |
|
|
Abstract In this paper, traditional Chinese medicine treatment of connective tissue disease-associated interstitial lung disease was discussed from the perspective of etiology and pathogenesis and treatment principles. It is believed that internal injury and deficiency are the root of the disease, invasion of external evil is the inducement of the disease, and the blocking of phlegm, stasis, and toxin is throughout the disease. In terms of treatment, the acute exacerbation period is based on dispersing cold and removing dampness, dispelling wind and clearing ligaments, while the stabilization period is based on tonifying the internal organs and harmonizing qi, blood, yin, and yang, and the whole process of treatment focuses on resolving phlegm and eliminating stasis and clearing heat and toxins.
|
|
|
|
|
[1] Spagnolo P,Distler O,Ryerson CJ,et al. Mechanisms of progressive fibrosis in connective tissue disease(CTD)-associated interstitial lung diseases(ILDs)[J]. Ann Rheum Dis,2021,80(2):143-150.
[2] 何奕坤,杨光辉.结缔组织病相关肺间质病变的病因病机探讨[J].四川中医,2015,33(4):32-34.
[3] 黄华,金燕樑,丁飞.儿童结缔组织性疾病相关间质性肺病的诊治进展[J].国际儿科学杂志,2020,47(11):768-772.
[4] 中国医师协会风湿免疫科医师分会风湿病相关肺血管/间质病学组.2018中国结缔组织病相关间质性肺病诊断和治疗专家共识[J].中华内科杂志,2018,57(8):558-564.
[5] Jee AS,Corte TJ. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease(CTD-ILD)[J]. Drugs,2019,79(14):1511-1528.
[6] 贺晋芳,晏军.从奇经论治结缔组织相关间质性肺疾病[J].浙江中医药大学学报,2020,44(10):967-972.
[7] 崔少欣.结缔组织病继发雷诺现象患者血清中sICAM-1、sVCAM-1和MCP-1的表达水平[D].石家庄:河北医科大学,2014.
[8] 吴童,李杰,李靖,等.探析从风论治结缔组织病相关间质性肺疾病[J].浙江中医药大学学报,2021,45(3):310-314.
[9] 李红华,曲妮妮.养阴益气活血方治疗结缔组织病相关间质性肺病疗效观察[J].辽宁中医药大学学报,2019,21(3):161-163.
[10] 曲妮妮,秦一冰,郑忻.益气养阴活血颗粒治疗结缔组织病相关间质性肺病(气阴两虚兼血瘀证)疗效评价[J].中华中医药学刊,2021,39(4):6-9.
[11] 刘洋,董振华,郝伟欣.原发性干燥综合征合并肺间质病变中医证候与高分辨CT特征的研究[J].北京中医药大学学报,2016,39(7):610-613.
[12] 李正富,吴德鸿,何兆春,等.范永升治疗系统性硬化病合并间质性肺病学术经验[J].中华中医药杂志,2020, 35(3):1269-1272.
[13] 魏丹,刘旻.温阳通络法治疗硬皮病继发肺纤维化验案一则[J].中国中医药信息杂志,2015,22(10):117-118.
[14] 于海静,曲妮妮.从痰瘀论治结缔组织相关性肺间质病[J].中医药临床杂志,2019,31(8):1417-1419.
[15] 凌嫘,范伏元.范伏元教授治疗结缔组织相关性肺间质病变经验[J].湖南中医药大学学报,2019,39(7):867-869.
[16] 王守法,曹建欣,赵丽薇.解毒安络汤治疗结缔组织病相关间质性肺病39例疗效观察[J].中医药导报,2012, 18(2):108-109.
[17] 张艳,徐丽萍.从“风、毒”探讨宋欣伟分期诊治结缔组织病相关间质性肺病[J].浙江中医药大学学报,2021, 45(8):829-834.
[18] 张丹,贾新华.雷公藤在结缔组织相关肺间质疾病中的临床应用及机理分析[J].中医药学报,2018,46(4):115-119.
[19] 陈琥,甘凤英,居艳娟,等.雷公藤多苷治疗结缔组织病相关间质性肺病的临床效果[J].中国当代医药,2020, 27(29):32-34.
[20] 陈红,王小超,陶丽菊,等.雷公藤多苷联合泼尼松治疗类风湿关节炎肺间质病变的临床疗效[J].世界中医药,2020,15(4):586-594.
[21] 唐丽娟,金连顺,张曈,等.张忠德以甄氏平调五脏法治疗间质性肺疾病经验[J].中医药导报,2019,25(2):131-133.
[22] 邓慧如.归芪补肺汤治疗结缔组织病相关性肺间质病变肺脾气虚、血瘀痰阻证的临床研究[D].长沙:湖南中医药大学,2015.
[23] 王婷,张彦奕,高敏.激素、炙甘草汤联合治疗结缔组织病所致间质性肺疾病疗效分析[J].中西医结合心血管病杂志,2019,10(7):144-145.
[24] 王玲,居来提·赛买提,杨卫江.生脉散加味治疗结缔组织病合并肺间质纤维化[J].中国现代医生,2011,49(11):48-56.
[25] 潘继波,张丽娜,方丽华,等.升补宗气法联合甲泼尼龙、环磷酰胺片治疗结缔组织病相关性间质性肺疾病的临床疗效[J].中国老年学杂志,2020,4(40):1436-1439.
[26] 程俊敏,吴霞,朱金月,等.从中医“肺痹、肺痿”来探析结缔组织病相关肺间质纤维化[J].时珍国医国药,2020, 31(3):668-669.
[27] 何兆春,李正富,吴德鸿,等.范永升治疗皮肌炎合并间质性肺病经验探析[J].中华中医药杂志,2020,35(4):1835-1839.
[28] 李松伟,王济华.结缔组织病相关肺间质病变的中医探讨[J].中华中医药杂志,2010,25(4):543-546.
[29] 胡谋波,吕军影.红花水煎液对博莱霉素诱导的硬皮病小鼠肺组织胶原含量的影响[J].风湿病与关节炎,2016, 5(9):5-8.
[30] 马鑫.益气活血膏方治疗间质性肺病肺脾气虚兼血瘀证患者的有效性与安全性的随机、对照的临床研究[D].乌鲁木齐:新疆医科大学,2019. |
|
|
|